Cerebrolysin dosage chart
60 mg Vial
Cerebrolysin is dosed at 20 mg–32 mg daily via subcutaneous injection in educational protocols. A 60 mg vial reconstituted with bacteriostatic water yields about 20 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water → 20 mg/mL concentration.
- Typical daily range
- 20–32 mg once daily (gradual titration); split doses for >20 mg.
- Easy measuring
- At 20 mg/mL, 1 unit = 0.01 mL = 200 mcg (0.2 mg) on a U‑100 insulin syringe.
- Storage
- Lyophilized at room temperature ≤25 °C (≤77 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days; do not freeze.
Dosing schedule
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 20 mg (20,000 mcg) | 100 units (1.0 mL) × 1 |
| Week 2 | 24 mg (24,000 mcg) | 60 units (0.6 mL) AM + 60 units (0.6 mL) PM |
| Week 3 | 28 mg (28,000 mcg) | 70 units (0.7 mL) AM + 70 units (0.7 mL) PM |
| Week 4+ | 32 mg (32,000 mcg) | 80 units (0.8 mL) AM + 80 units (0.8 mL) PM |
Reconstitution steps
- 1Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 2Inject slowly down the vial wall; avoid foaming.
- 3Gently swirl/roll until dissolved (do not shake).
- 4Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 7 days.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose, timing (AM/PM), and site rotation to maintain consistency.
- For doses exceeding 100 units (1.0 mL), split into two separate injections at different sites.
How This Works
Cerebrolysin is a multicomponent peptide preparation derived from porcine brain tissue, containing biologically active neuropeptides and amino acids with molecular weights below 10 kDa. This low molecular weight allows it to cross the blood–brain barrier and exert neurotrophic effects similar to endogenous factors like nerve growth factor (NGF) and brain‑derived neurotrophic factor (BDNF). Preclinical studies demonstrate neuroprotective effects including reduced infarct size and improved recovery in ischemia models. Human trials have examined its use in stroke, dementia, and traumatic brain injury with mixed but generally favorable tolerability profiles.
Potential Benefits & Side Effects
Observations from preclinical and clinical literature.
- Preclinical models consistently show neuroprotective effects including reduced neuronal damage and improved functional recovery after ischemic insult.
- Meta‑analyses of human dementia trials suggest modest cognitive benefits with daily IV infusions; stroke trial results have been more variable.
- Generally well tolerated in short‑term use; occasional mild injection‑site reactions (redness, discomfort) may occur with subcutaneous administration.
- Rare reports of dizziness, headache, or gastrointestinal upset; discontinue and consult a professional if significant adverse effects occur.
Lifestyle Factors
Complementary strategies for best outcomes.
- Maintain a nutrient‑dense diet rich in omega‑3 fatty acids, antioxidants, and B‑vitamins to support neuronal health.
- Engage in regular aerobic exercise and cognitive stimulation to reinforce neuroplasticity.
- Prioritize quality sleep (7–9 hours) and stress management to optimize recovery and brain function.
- Avoid excessive alcohol and other neurotoxic substances during the protocol.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources.
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a 2–4 cm skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
- For split‑dose protocols (AM/PM), use different injection sites for each administration.
important-note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
Cerebrolysin dosage FAQs
How much bacteriostatic water do you use to reconstitute Cerebrolysin?
Add 3.0 mL bacteriostatic water → 20 mg/mL concentration. for a 60 mg Vial vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.
What does the Cerebrolysin dosing schedule look like?
Week 1 — 20 mg (20,000 mcg) — 100 units (1.0 mL) × 1; Week 2 — 24 mg (24,000 mcg) — 60 units (0.6 mL) AM + 60 units (0.6 mL) PM; Week 3 — 28 mg (28,000 mcg) — 70 units (0.7 mL) AM + 70 units (0.7 mL) PM; Week 4+ — 32 mg (32,000 mcg) — 80 units (0.8 mL) AM + 80 units (0.8 mL) PM. The full table above lists every step with matching syringe units.
What are the mixing steps for Cerebrolysin?
Draw 3.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl/roll until dissolved (do not shake).
How should reconstituted Cerebrolysin be stored?
Storage: Lyophilized at room temperature ≤25 °C (≤77 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days; do not freeze..
How many insulin syringe units equal a Cerebrolysin dose?
Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.
Is Cerebrolysin approved for human use?
No. Cerebrolysin is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.
Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.
On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.